Form 4: Phibro Animal Health CEO Sells Shares

Phibro Animal Health Corporation's President and CEO, Jack Bendheim, along with BFI Co., LLC, reported the sale of 213 shares of Class A Common Stock at $40.16 per share under a pre-arranged trading plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, reported a sale of Class A Common Stock.
• A total of 213 shares of Class A Common Stock were disposed of on January 9, 2026.
• The shares were sold at a price of $40.16 per share.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Following the transaction, BFI Co., LLC indirectly holds 38,659 shares, and Jack Bendheim directly holds 16,840 shares.

Sentiment

Score: 5

Explanation: Neutral. The sale is a small amount and was conducted under a pre-arranged 10b5-1 plan, which typically mitigates negative sentiment associated with insider selling. It's a routine disclosure.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, though the small amount in this transaction is unlikely to be significant.

Future Outlook

na

Industry Context

This filing is a routine insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Related Party Transactions

• The sale of 213 shares of Class A Common Stock by Jack Bendheim, President and CEO, Director, and 10% owner, and BFI Co., LLC, a 10% owner over which Mr. Bendheim exercises control, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by a key executive and 10% owner, even under a 10b5-1 plan, could be interpreted in various ways, but the impact is likely minimal due to the small volume.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this routine insider transaction filing.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider sale of a very small number of shares by the CEO and a related entity. Such a transaction, especially under a 10b5-1 plan, typically does not signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Investors should continue to hold based on broader company performance and market conditions, not this specific transaction.

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, BFI Co. LLC, Insider Sale, Form 4, SEC Filing, Stock Transaction, 10b5-1 Plan, Class A Common Stock